operational as focus the first companies I and be and in of greatly more no of has burn, everyone the us scale thesis of costs the cash operators reduced year of I while We to business closing disciplined and BioTools declining operations BioTools, in fully successful the business this Standard fragmented for growth. can gross no David. maintaining margins of memory, merger full space the was recent life you, to SomaLogic, highly science maxim, appreciate Standard with expanded could joining excitement, Add a and one accomplishment. In say the a margin, build to returned our our significantly our Thank today's and times not its team team on call.
XXXX challenging proud more activated all-important now recognizing navigating with mission.
full genomics technologies certainly highly pro in era. With not combined $XXX combined revenue Factor end forma merger but and spatial speed XXXX as recent sheet the a certainly a and as generated X runner can in the roof, company we at 'XX million the SomaLogic broadest the next one on representing generation business customer combined the with cash differentiated the of the pro solutions positions completion are in of biology I marketed X, in serving business balance January the of the only ahead. forma proteomic in and on under say beyond today the front in million $XXX
still it's diversified early foundation leader our much as more and mission be validation better to building with life to XXXX so become year and While of look our to in science days a of done, do tools back world-changing at research. customers I a empower
initiatives today's will During competitive success. objectives, portfolio XXXX the review call, will provide combined our position enhanced thoughts critical our business our against strategic of position product and finally, objectives summary highlight performance and those review on I our we near-term expect a for and briefly
our progress execution our in measure Objective standardized Standard operational the guide culture XXXX Taich that operating Systems we instill enhance more business you I'll and to comments, uncompromising XXXX. should Jeff's organization the XXXX.
To as what a quarter my performance. other, These call who and we Adam the as begin, on and top and operating year the let important focus it's or objectives, and analysis forward combined highlighting process section, and efficiency progress and platform, the will each SBS the BioTools discipline of fourth and with are profitability. full call. turn of drive At our in to we detailed financial over X, the will lean against. strategy which a our objectives provide Following known our Jeff restate advance Black, are drive business integration fuel me approach Business From equally this talk X as our of conclusion
cash in a points non-GAAP million end, deliver delivered expansion, that in X, life science profitably including $XX XX% margin basis and and of and a platform meaningful reduction for Objective our this over gross customers. XX% enabling in $XXX breakthrough can technologies we million To scaled operating services expenses progress and create XXX non-GAAP XXXX operating use. improvement
no mission bringing stated is heavily science and roof life before, tools solutions important in margin, unprofitable there's I one and without fragmented As under together the crucial space.
has model margin mix a promises a broad differentiated a a and being services only recurring of the plan of business that with customers recent activated amassing that and percent expanding markets in platforms, model better reach of distributed our across revenue.
The the really gross is and of business diverse are together highly end our fully. instruments SomaLogic We space proven portfolio to set date model merger consumables XX-plus of and building across
operational integration successful platforms, laser-focused in new potential business broad This businesses on with team identify with but underappreciated compelling the burdened to acquisitions the includes SomaLogic, this team proven landscape. development continues overly With and technologies, stellar teams. emerging
businesses these family. Our and opportunities Bio goal is products, partners Standard to people the as into approach these bring and
core business $XXX than by XX% of new revenue future year-over-year, margin return We that our well, our to growth indicator third fuel installed only Hyperion and of recurring to a are to consumables but services scale.
This more leads me base. challenging strategy but technologies, will growth and and XXXX with led X% pleased customer differentiated total in million, Against representing gross objective, collective confident also over growth more imaging with to up as critical growth. our environment, truly see revenue revenue when drive leading system. this report executed customers of revenue diversify growth empower will our expanding not placements fuel the macroeconomic careful XXXX instrument We a XTi across at instruments revenue and with in I'm an
in the in revenue revenue SomaLogic with excluding addition, $XX XX% total core over revenue and royalty XXXX. in million when team certain In growth delivered revenues growth XXXX solid nonrecurring
combined in in the setting XXXX, to expanded distributed X On to $XXX our us operating from growth scale a business. basis, kits its XX forma delivered a achieving site step authorized also for the in XXXX for business revenue SomaLogic up activating footprint has of business. pro million major
On all this objective, I share given will comment growth business the and while at cost, expanding market expense add of just was customer at has segment industry that one pursued from fundamentals. emerged the
capital appreciate up recognize We underfunded be profitability with market and/or secure the deeply as an it it must sense in for need be always experience While existential without that also pursued value. path when risk discounted have shareholder values. long-term to growth, it eye those dried the with but usually cash, may made BioTools and will to profitability, and a the at flushed does, and Standard
you sustaining our build to commit work value. shareholders We for to and
customers and disciplines, distinct customers our service. we biopharma and across business research This and enable the BioTools in product largely our instruments, serves genomics. categories, offering we review including proteomics omic conduct now two scientific While and distinct academic SomaScan consumables, service instrument to our research, Standard field-based
are gross expense life revenue. XXXX target Consumables a represented consumables some service profile margin with and consumable once cycles pull-through. of have sciences our capital the long products of installed, attractive in life a with north Today, XX% larger product, but of XX%. most Instruments future over are
to future attractive margin leading consumables believe new today XX% business of of current XX% and sales this grew as recurring XX% instrument about north services a a and has with generally of target represents margins. sales instrument lead Our field-based indicator our in XXXX. We gross revenue is of growth and
revenue in by And SomaLogic this of becomes part services the today of legacy XXXX, is Most revenue driven our businesses. our SomaScan mix.
Our range trial XX% the discovery accounts with has biopharma Today, the and concentrated XXX elite running biopharmaceutical programs a of the revenue now and many customer companies. is customers, in in top in this relationships XX margin predominantly including pipeline. gross large traction clinical profile over also carries large-scale
concentrated, is business revenue lumpy project-based from this and can highly Given be quarter-to-quarter.
business. our the Adam margin revenue expand continue and predictability. gross lean to principles his And this team consistency profile customer enhance and will that base and made improve the apply diversify and will We progress of the to we SBS
continue our consumable to technology leverage great broader with continue over reach customer We way broaden our drive SomaScan opportunity a will best-in-class time excited offering, expanded XXXX. our execute legacy, service through and further XX sites to to to to mix for evolve certified should to on relationship the and which revenue. customer see our model academic We're base. our also in program, as sites relationships, research the about Illumina. commercial authorized We opportunity commercial this BioTools This Standard sites higher-margin
field blueprint function, technologies of blueprint is opened our exciting an the of business believe of we the eyes next-gen the company to but we that fast-growing proteome the in Within with end the are X and and proteomics, portfolio. Genomics only research. human
quality First, spatial our proteomics throughput Hyperion and XTi space. highest imager has data the the in
that CyTOF same immune cell profiling technology than at the the time. distinguish XX can more extracellular Second, and markets is intracellular only
proteome SomaScan Third, of coverage and starting lowest in the CV. 'XX, proteomics our offers highest the plasma
in and prospective pull-through. solution existing in of Hyperion XTi legacy we system's The year-over-year In market-leading business BioTools launch an the be quality customers We model by research. to imaging workflow that consumable to will launch a workflow to plan the by proteomics system very half of major the new throughput our emerging extension Standard a well our a received proteomics first of customer and spatial XXXX over growth. increase and field as improve that of time, as translational to XX% data grow in continues contributor with returned for XXXX,
is do of using by This can only customers is of and intracellular biological extracellular important an technologies. that point insights in both Flow competing the differentiation XXXX. technology enabling high CyTOF go markers gain that markers, should would number support and help growth our a unnoticed to otherwise
customer differentiated solution the important proteome expansion of With the we for platform of discovery drug broadest biopharma addition and an and coverage for new of accounts, the of compelling important SomaScan the have biomarkers targets. key enabling
the expect XX%. million was with loss product, while of achieved to. of can market expect genomics revenue and in total a Furthermore, growth us. in down discipline and margin over compared excluding core contribution a traditionally X% XXXX. a you In the grew more plays loss of $XXX,XXX Bio discontinued the $XX legacy small of genomics the XXXX, near revenue we business This from where In is Standard authorized than X% site SomaLogic expansion, type XXXX, the business to positive in impact academic
the sequencing of a backbone science for the innovation the and life with has event of [indiscernible] the Genomics fast biology. golden years. been cheap last fueled discovery And has XX next-generation age
a for also over our genomics and competitive price increasing with the competition market highly past strategic costs greatly sensitivity years. remains as asset have business While a sequencing us, reduced next-gen several it's
Post and and margin. its we significantly and consolidated we expect being provider expanded our business on in of continued X, this the accounts return major portfolio and strategic drive margin. targeting installed our partner, with on enabler XXXX only a key strategic To incremental a set delivered to base from have contribution focus that genomic to the managing we to to enhance With and approach, an segment commercial growth this platform, the spend incrementally OEMs have prudently if core invest to and will end, focus we the while additional near-term OEM growth Genomics in reposition, we solid X Biomark customers. segment's reduced XX. OEM help high-volume progress instruments our it contribution are From
with second focus the a In our reflects of agreement NGD Gen bringing broaden fact, OEM with will expertise sectors growth earlier this as the pathogen in and This week, we of strategy, microfluidic Diagnostics partnership of the vital our sample OEM life field preparation agreement. major our impact Next platform of advancement announced that long-term across science. domain
execution As life operational for we're our have space. I just mentioned of and started. the science lies with merger that work tools strong with we foundation close position we're But to in a leadership established the earlier, getting successful SomaLogic, not the ahead, naive a
XXXX ahead, As clear over and we road key here beyond, and staying we and what a can committed next look map to drivers delivering is you of of us. have to the expect remainder months quarters the from of value
integration the when We're to are strategic over the of with work May priorities. of and discipline on meantime, on on sight of prioritization remain earnings In to merger in X and expect quarters the report plan operating underway shown running leadership the assumed line focused business well integration We tactical we Standard clear look to others. decisions forward since call with level past strategic merger and more provide at our on progress several same initial to activities BioTools. do on QX we we've and XX-day continued operating we initiatives. our that First, an our update pleased strategic,
current annual the is expense cost compared delivery combined several across To deliver operating million expect reiterate, run our the work Second, by approximately cost operating shared will place. $XX focus half This with synergies rate XXXX the a on XXXX. already synergies commitments. to first for in our in we of joint merger organization streams
half in two take see a in operating or particularly begin these reductions it to expenses operating result, the our see in show to meaningful to the XXXX, non-GAAP While of expect second would we up efforts G&A. quarter in
implemented expect our annualized quarter. and fourth the have of target of We more $XX million by to synergies the than XX% end or operationalized
range Third, continued over progress both that across to to revenue call financial is guidance pipeline will from we Still, we the the growth and into are turn play continued combined providing headwinds of and a profile continuing full growth good and way. XXXX setup internal $XXX priorities year traction merger for on of updates providing provided you along backdrop confident uncertainties our for industry. of patience, growing revenue X%. to ability the Jeff? to a with take macroeconomic see we against integration in the an focus in X% we expanded This our of I'll remain confident now more to but opportunities Jeff and beyond.
This for we on XXXX growth. Today, million quarter results. million, implying XXXX revenue to in time, and commentary detailed all fourth the deliver, $XXX look forward our
